Howard Lutnick? Scott Bessent? Marc Rowan? Kevin Warsh? The president-elect’s list of candidates has grown longer, clouding ...

Patients with GPA completely weaned off glucocorticoids were four times as likely to flare compared with those kept on a low ...

Donald Trump has delivered a blow to the drug makers he claims hampered his 2020 election bid with the appointment of vaccine ...

Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist ...

High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. Here's why these two high-yield ...

Though the strategic shift allows pharma to offer integrated health solutions, diversify revenue and improve patient outcomes ...

Pfizer's drug approvals and advertising revenue could be affected by RFK Jr.'s potential appointment. See why PFE stock is a ...

Drug manufacturers saw their stock prices fall on Friday after vaccine skeptic Robert F. Kennedy Jr. was announced as Trump's ...

A U.S. stock rally fueled by Donald Trump’s election victory is stumbling, as investors contend with everything from renewed ...

Pfizer is currently assessing the potential divestiture of its hospital drugs unit, a division mainly focused on antibiotics ...

For young, healthy people who may be wondering, “do I need a COVID booster at all?”, having one annually is sensible.

Pfizer's stock underperforms the S&P 500, facing patent expirations and competition, yet offers a 6.3% forward dividend yield. Despite a positive Q3 earnings surprise, profitability remains weaker ...